Publication | Closed Access

A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI™), in patients with advanced solid tumours

OncologyMedicineAdvanced Solid TumoursEscalation StudyAnti-cancer AgentZk 304709Cancer TreatmentPharmacologyRadiation OncologyCancer ResearchCancer Growth